Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.
A recent study comparing usage of the infliximab biosimilar Inflectra (infliximab-dyyb; CT-P13) with that of the originator biologic (Remicade) among Medicare beneficiaries found that use of the biosimilar is increasing even though it accounted for less than 10% of total monthly administrations.
Study data also suggest some beneficiaries are switching from the reference product to the biosimilar. However, analyses by indication and prescribing clinician suggest that patients and physicians may still have concerns about extrapolation to gastrointestinal indications, according to the authors.
The study, published in the Journal of General Internal Medicine, examined the demographics, usage, and uptake patterns of Remicade and Inflectra in the infliximab-eligible Medicare fee-for-service population in the United States from July 2016 to December 2018. “The overall uptake of biosimilar infliximab has been much slower than that of the biosimilar filgrastim, the first biosimilar product to enter the US market,” the authors noted.
The demographics for the populations treated with the reference product and biosimilar were “broadly similar,” with differences by geographical region. Greater percentages of biosimilar-treated patients were found in the Midwest and West, as opposed to greater percentages for the originator in the Northeast and South.
A breakdown of the biosimilar and originator-treated populations by indication determined the biosimilar was administered somewhat less for inflammatory bowel disease (IBD), which encompasses ulcerative colitis (UC) and Crohn disease (CD). Gastrointestinal indications accounted for 22.5% and 25.9% of treatments with the biosimilar and originator, respectively.
The authors said 17.4% and 15.3% of patients treated for CD received the reference drug and biosimilar, respectively. UC accounted for 8.5% and 7.2% of patients on the originator versus the biosimilar.
Analyzing by prescribing clinician, the authors found that gastroenterologists prescribed the biosimilar less often (14%) compared with the reference product (17%), whereas oncologists prescribed the biosimilar more commonly (10.5%) than the reference product (5.5%). Rheumatologists prescribed the biosimilar and reference product in the same proportions (58.2% and 59.9%, respectively).
The authors observed a relative reluctance to prescribe biosimilars for gastrointestinal indications. “There may still be some reservations among certain patients or providers regarding usage of the product for indications extrapolated from the overall conclusion of biosimilarity” between the reference and biosimilar agents, they wrote.
The use of the infliximab biosimilar in CD and UC was originally extrapolated from the demonstration of similarity to the reference product in clinical studies on patients with rheumatoid arthritis (RA). Notably, 55.02% of patients being treated for RA received the biosimilar. The percentage receiving the reference product was 52.24%.
Patients taking the reference product and those taking the biosimilar were more likely to have prior use of the reference product,“which indicates that some beneficiaries are switching from the reference product to the biosimilar,” according to the authors.
The dose patterns across different indications were similar for those using the originator versus the biosimilar. This was notable in CD, where “the label for each product specifies that increasing the dose to 10 mg/kg may benefit patients who have lost their response.” The authors said the similar dose distributions in CD suggest that the “biosimilar has not required more dose escalation than the reference product.”
The authors recommended further study of infliximab biosimilars in IBD, attention to clinicians’ rationale for their prescribing choices, and more effort to educate patients and physicians about biosimilars.
Reference
Kozlowski S, Flowers N, Birger N, et al. Uptake and usage patterns of biosimilar infliximab in the Medicare population. J Gen Intern Med. Published online June 23, 2020. doi:10.1007/s11606-020-05957-1
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.